Loading stock data…
SELLAS Life Sciences Group, Inc (SLS)
$11.32-1.02 (-8.27%)
Market ClosedLast close Jul 24
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SELLAS Life Sciences Group, Inc. in the Healthcare sector is trading at $11.32 with a market capitalization of $1.6B. Wall Street consensus targets $27.50 (2 analysts), implying a +142.9% move over the next 12 months. The stock is currently 29% below its 52-week high of $15.88, remaining 118.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +142.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.25M↓ | -$8.26M↓ | -$7.08M↓ | -$6.87M↓ | -$6.06M |
| Net Income | -$8.41M↓ | -$7.66M↓ | -$6.79M↓ | -$6.60M↓ | -$5.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.42%
Volume
Today's trading volume
6.65M
Recent News
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer
During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance
A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas
Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.
SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout
Sellas is preparing for database lock, potential BLA-related regulatory work, and development of SLS009, its second AML drug.
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance
The company entered a quiet period for trial-specific updates ahead of topline data.